AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35240263 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (WP) 20 g at breakfast + 20 g at dinner
Number of subjects: 31
Study 35240263 — intervention group
Group type: COMPARATOR
Intervention: Placebo-maltodextrin (PL) 20 g at breakfast + 20 g at dinner
Number of subjects: 31
Study 35240263 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (WP)
Number of subjects: 31
Study 35240263 — intervention group
Group type: COMPARATOR
Intervention: Placebo-maltodextrin (PL)
Number of subjects: 31
Study 33258114 — intervention group
Group type: COMPARATOR
Intervention: lanadelumab total group
Number of subjects: 125
Study 33258114 — intervention group
Group type: COMPARATOR
Intervention: lanadelumab 300 mg q2wks
Number of subjects: 125
Study 32167001 — intervention group
Group type: EXPERIMENTAL
Intervention: D-alanine (60 mg/kg)
Number of subjects: 63
Study 32167001 — intervention group
Group type: EXPERIMENTAL
Intervention: D-serine
Number of subjects: 63
Study 32167001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 35461158 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (5 mg)
Number of subjects: 32
Study 35461158 — intervention group
Group type: COMPARATOR
Intervention: Xeljanz® (5 mg)
Number of subjects: 32
Study 34001952 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel biomarkers of PCa tumors discovered through cross-cancer learning
Number of subjects: 0
Study 34001952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-cancer learning approach
Number of subjects: 0
Study 34001952 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of discovered biomarkers
Number of subjects: 0
Study 32738878 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-Fowler's position
Number of subjects: 141
Study 32738878 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 141
Study 32929234 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC inhibitor (pharmacologic inhibition of acetyl‐CoA carboxylase)
Number of subjects: 0
Study 32929234 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 35388465 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAG-Ida
Number of subjects: 94
Study 35388465 — intervention group
Group type: COMPARATOR
Intervention: DClo
Number of subjects: 94
Study 33070170 — intervention group
Group type: EXPERIMENTAL
Intervention: Horticultural Therapy (HT) intervention over 6 months
Number of subjects: 59
Study 33070170 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 59
Study 32713326 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient controlled analgesia pump
Number of subjects: 200
Study 32713326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent analgesia application
Number of subjects: 200
Study 33723969 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation group (n = 11) with home-based exercise, nutritional, and dietary advice delivered via smartwatch
Number of subjects: 22
Study 33723969 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 11) receiving usual care with smartwatch as placebo
Number of subjects: 22
Study 32827226 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drink consumption
Number of subjects: 3688
Study 32827226 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drink consumption frequency
Number of subjects: 3688
Study 32827226 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of first intake
Number of subjects: 3688
Study 32827226 — intervention group
Group type: EXPERIMENTAL
Intervention: High consumption
Number of subjects: 3688
Study 32827226 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for consumption
Number of subjects: 3688
Study 35785530 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine
Number of subjects: 700
Study 35785530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study 35785530 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 viral copies at diagnosis
Number of subjects: 700
Study 33445959 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal and Social Rhythm Therapy (IPSRT)
Number of subjects: 0
Study 33445959 — intervention group
Group type: EXPERIMENTAL
Intervention: IPSRT
Number of subjects: 0
Study 33588758 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg once a day)
Number of subjects: 20
Study 33588758 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 20
Study 35575171 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week web-intervention (n=20)
Number of subjects: 41
Study 35575171 — intervention group
Group type: COMPARATOR
Intervention: wait-list control (n=21)
Number of subjects: 41
Study 33038079 — intervention group
Group type: EXPERIMENTAL
Intervention: Comarum palustre L. tablets 500 mg twice daily for 28 days
Number of subjects: 15
Study 32142119 — intervention group
Group type: COMPARATOR
Intervention: Incident obesity at 43 years (vs never) in 1946-NSHD
Number of subjects: 11001
Study 32142119 — intervention group
Group type: COMPARATOR
Intervention: Incident obesity at 53 years (vs never) in 1946-NSHD
Number of subjects: 11001
Study 32142119 — intervention group
Group type: COMPARATOR
Intervention: Persistent obesity from 36 years in 1946-NSHD
Number of subjects: 11001
Study 32142119 — intervention group
Group type: COMPARATOR
Intervention: Inactivity as a mediator for incident obesity at 43 years in 1946-NSHD
Number of subjects: 11001
Study 32142119 — intervention group
Group type: COMPARATOR
Intervention: Inactivity as a mediator for incident obesity at 53 years in 1946-NSHD
Number of subjects: 11001
Study 32142119 — intervention group
Group type: COMPARATOR
Intervention: Inactivity as a mediator for persistent obesity from 36 years in 1946-NSHD
Number of subjects: 11001
Study 32142119 — intervention group
Group type: COMPARATOR
Intervention: Patterns of association in 1958-NCDS
Number of subjects: 11001
Study 35066880 — intervention group
Group type: EXPERIMENTAL
Intervention: ADJ
Number of subjects: 1093
Study 35066880 — intervention group
Group type: EXPERIMENTAL
Intervention: DEP
Number of subjects: 1093
Study 35066880 — intervention group
Group type: COMPARATOR
Intervention: CONT
Number of subjects: 1093
Study 34506964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouse allergen reduction
Number of subjects: 297
Study 34506964 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower indoor PM10 levels
Number of subjects: 297
Study 34506964 — intervention group
Group type: COMPARATOR
Intervention: Sensitization and exposure to other indoor allergens
Number of subjects: 297
Study 33534226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics only
Number of subjects: 186
Study 33534226 — intervention group
Group type: COMPARATOR
Intervention: Appendectomy
Number of subjects: 186
Study 32444407 — intervention group
Group type: EXPERIMENTAL
Intervention: Downhill walking training (DT)
Number of subjects: 35
Study 32444407 — intervention group
Group type: COMPARATOR
Intervention: Conventional training (CT)
Number of subjects: 35
Study 34518652 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide plus androgen deprivation therapy (ADT)
Number of subjects: 0
Study 34518652 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus androgen deprivation therapy (ADT)
Number of subjects: 0
Study 34518652 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0
Study 34518652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33688697 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous video-EEG (cEEG, lasting hours to several days)
Number of subjects: 0
Study 33688697 — intervention group
Group type: COMPARATOR
Intervention: Routine video-EEG (rEEG, lasting 20-30 min)
Number of subjects: 0
Study 32887570 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-to-stand (STS) exercises combined with Oral Nutritional Supplements (ONS) intake
Number of subjects: 23
Study 35621877 — intervention group
Group type: COMPARATOR
Intervention: No anti-HBV (Zidovudine + intrapartum nevirapine + 1 week of tenofovir disoproxil fumarate and emtricitabine)
Number of subjects: 138
Study 35621877 — intervention group
Group type: EXPERIMENTAL
Intervention: 3TC (3TC + Zidovudine + LPV/r)
Number of subjects: 138
Study 35621877 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC-TDF (FTC + TDF + LPV/r)
Number of subjects: 138
Study 35621877 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC-TDF
Number of subjects: 138
Study 35621877 — intervention group
Group type: COMPARATOR
Intervention: No anti-HBV
Number of subjects: 138
Study 35621877 — intervention group
Group type: EXPERIMENTAL
Intervention: 3TC
Number of subjects: 138
Study 35621877 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal HBeAg positive
Number of subjects: 138
Study 34732197 — intervention group
Group type: EXPERIMENTAL
Intervention: On-X Mechanical Prosthesis
Number of subjects: 855
Study 34732197 — intervention group
Group type: COMPARATOR
Intervention: St Jude Medical Mechanical Prosthesis
Number of subjects: 855
Study 34732197 — intervention group
Group type: EXPERIMENTAL
Intervention: Western World Population
Number of subjects: 855
Study 34732197 — intervention group
Group type: EXPERIMENTAL
Intervention: Developing World Population
Number of subjects: 855
Study 33408261 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandage
Number of subjects: 62
Study 33408261 — intervention group
Group type: COMPARATOR
Intervention: Casting
Number of subjects: 62
Study 36145090 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina maxima 70% ethanol extract (SM70EE) 1 g/day
Number of subjects: 80
Study 36145090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 33097279 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated with live LaSota ND vaccine (CV)
Number of subjects: 128
Study 33097279 — intervention group
Group type: EXPERIMENTAL
Intervention: Administered ND vaccine and 0.25 mg/kg body weight (BW) LPS (L‐LPS)
Number of subjects: 128
Study 33097279 — intervention group
Group type: EXPERIMENTAL
Intervention: Administered ND vaccine and 0.5 mg/kg BW LPS (H‐LPS)
Number of subjects: 128
Study 33097279 — intervention group
Group type: COMPARATOR
Intervention: Normal control (NC)
Number of subjects: 128
Study 33097279 — intervention group
Group type: EXPERIMENTAL
Intervention: ND vaccination combined LPS
Number of subjects: 128
Study 36252937 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care augmented with a culturally adapted version of Caring Contacts (12 months, 25 messages)
Number of subjects: 0
Study 36252937 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (control)
Number of subjects: 0
Study 33394904 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS with intensive speech therapy (ST)
Number of subjects: 30
Study 33394904 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 times a day low-frequency rTMS with intensive speech therapy (ST)
Number of subjects: 30
Study 33394904 — intervention group
Group type: COMPARATOR
Intervention: Control group (intensive speech therapy only)
Number of subjects: 30
Study 34618409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernosal injection (ICI) of 100 units of BoNT‐A in 2 ml of saline
Number of subjects: 70
Study 34618409 — intervention group
Group type: COMPARATOR
Intervention: 2 ml of saline (control)
Number of subjects: 70
Study 33389302 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving Training Program (10 driving lessons with a professional driving instructor)
Number of subjects: 72
Study 33389302 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 72
Study 32978449 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3-ppm ozone for two hours
Number of subjects: 17
Study 32978449 — intervention group
Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 17
Study 35030410 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid esophagectomy
Number of subjects: 0
Study 35030410 — intervention group
Group type: COMPARATOR
Intervention: Open esophagectomy
Number of subjects: 0
Study 35030410 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline role functioning score increase by 10 points
Number of subjects: 0
Study 35030410 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue score increase by 10 points
Number of subjects: 0
Study 35030410 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain score increase by 10 points
Number of subjects: 0
Study 35030410 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pain score
Number of subjects: 0
Study 35030410 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher insomnia score
Number of subjects: 0
Study 35030410 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal adenocarcinoma diagnosis
Number of subjects: 0
Study 33044793 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (12 mg orally once daily for patients with a baseline body weight ≥60 kg and 8 mg orally once daily for patients with a baseline body weight <60 kg)
Number of subjects: 954
Study 33044793 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib (400 mg orally twice daily)
Number of subjects: 954
Study 33044793 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 954
Study 33044793 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 954
Study 34708415 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal relational role analysis (IRRA)
Number of subjects: 10
Study 34708415 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study 34530868 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth, CPN‐administered decision support intervention
Number of subjects: 0
Study 34530868 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 0
Study 32447767 — intervention group
Group type: EXPERIMENTAL
Intervention: Jessner's solution (JS)
Number of subjects: 36
Study 32447767 — intervention group
Group type: COMPARATOR
Intervention: Salicylic acid (SA) 30%
Number of subjects: 36
Study 35436290 — intervention group
Group type: EXPERIMENTAL
Intervention: T13‐Jeevamrut 16.08 L plant‐1 + Vermicompost 24.79 kg plant‐1
Number of subjects: 42
Study 34376536 — intervention group
Group type: EXPERIMENTAL
Intervention: Early high-dose glucocorticoids (GCC) use (≥60mg prednisone equivalent qd) after irAE onset
Number of subjects: 947
Study 34376536 — intervention group
Group type: EXPERIMENTAL
Intervention: Early high-dose GCC use
Number of subjects: 947
Study 34376536 — intervention group
Group type: EXPERIMENTAL
Intervention: Accumulated GCC exposure
Number of subjects: 947
Study 34376536 — intervention group
Group type: COMPARATOR
Intervention: Control group (irAE without early high-dose GCC use)
Number of subjects: 947
Study 32326815 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-stage caregiver support intervention (provided 5 days before transplant, 14 days after transplant, and 1 week before discharge)
Number of subjects: 45
Study 32326815 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-stage caregiver support intervention
Number of subjects: 45
Study 32326815 — intervention group
Group type: COMPARATOR
Intervention: Standard support provided in the hospital ward (control group)
Number of subjects: 45
Study 35768108 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes to diet and/or physical activity (PA) as part of a factorial randomised controlled trial
Number of subjects: 17
Study 33887514 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 gastrectomy
Number of subjects: 267
Study 33887514 — intervention group
Group type: COMPARATOR
Intervention: D1 gastrectomy
Number of subjects: 267
Study 32058596 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g of octanoic acid‐rich MCT (OAR)
Number of subjects: 0
Study 32058596 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g of decanoic acid‐rich MCT (DAR)
Number of subjects: 0
Study 32058596 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g of MCT (OAR or DAR)
Number of subjects: 0
Study 32058596 — intervention group
Group type: COMPARATOR
Intervention: 0 g of MCT (control)
Number of subjects: 0
Study 35395951 — intervention group
Group type: EXPERIMENTAL
Intervention: felzartamab (16 mg/kg per infusion)
Number of subjects: 20
Study 35395951 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 35395951 — intervention group
Group type: EXPERIMENTAL
Intervention: felzartamab
Number of subjects: 20
Study 33792490 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer patients
Number of subjects: 292
Study 33792490 — intervention group
Group type: COMPARATOR
Intervention: Non-cancer patients
Number of subjects: 292
Study 36463655 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-based physical activity program (24 sessions, 40 min each, twice a week)
Number of subjects: 23
Study 33226501 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment plus daily supplementation of oral probiotics (≥ 1 × 10^9 live cells of Streptococcus thermophilus ST10, ≥ 1 × 10^9 live cells of Lactococcus lactis LCC02, ≥ 1 × 10^9 live cells of Lactobacillus delbrueckii subsp. bulgaricus)
Number of subjects: 26
Study 33226501 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (lid hygiene, warm compression and dexamethasone/tobramycin ointment for at least 20 days)
Number of subjects: 26
Study 35276963 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4000 IU daily for 12 weeks)
Number of subjects: 530
Study 35276963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study 34533466 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based treatment for urinary incontinence
Number of subjects: 17
Study 33509974 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ingestion of MSG
Number of subjects: 16
Study 33509974 — intervention group
Group type: COMPARATOR
Intervention: Topical application (swishing) of MSG
Number of subjects: 16
Study 32366156 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC of empagliflozin 5 mg/linagliptin 2.5 mg/metformin XR 1000 mg
Number of subjects: 60
Study 32366156 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC of empagliflozin 25 mg/linagliptin 5 mg/metformin XR 1000 mg
Number of subjects: 60
Study 32366156 — intervention group
Group type: COMPARATOR
Intervention: Free tablet combinations of empagliflozin/linagliptin/metformin XR
Number of subjects: 60
Study 34864785 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained WHO risk drinking reductions of 2 or more levels throughout treatment
Number of subjects: 964
Study 34864785 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of exactly 1 level
Number of subjects: 964
Study 34242837 — intervention group
Group type: EXPERIMENTAL
Intervention: adaptive dual n-back training
Number of subjects: 60
Study 34242837 — intervention group
Group type: COMPARATOR
Intervention: non-adaptive 1-back training
Number of subjects: 60
Study 32997744 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate isoniazid preventive therapy (IPT) during pregnancy
Number of subjects: 925
Study 32841554 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole Lauroxil 441 mg every 4 weeks
Number of subjects: 478
Study 32841554 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole Lauroxil 882 mg every 4 weeks
Number of subjects: 478
Study 33820572 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (600 μg RAE/d)
Number of subjects: 279
Study 33820572 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (10 μg/d)
Number of subjects: 279
Study 33820572 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Vitamin A (600 μg RAE/d) and Vitamin D (10 μg/d)
Number of subjects: 279
Study 33820572 — intervention group
Group type: COMPARATOR
Intervention: Standard anti-tuberculosis treatment alone (Control group)
Number of subjects: 279
Study 33873154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 8
Study 33873154 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery-stress questionnaire for athletes
Number of subjects: 8
Study 34233913 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of allogenic cardiosphere-derived cells (CDCs)
Number of subjects: 142
Study 34233913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 32946280 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 452
Study 36207033 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS-intervention to reduce incidence of unintended pregnancy
Number of subjects: 866
Study 36207033 — intervention group
Group type: EXPERIMENTAL
Intervention: Not using a highly effective contraceptive
Number of subjects: 866
Study 36207033 — intervention group
Group type: EXPERIMENTAL
Intervention: Having ever experienced intimate partner violence (IPV)
Number of subjects: 866
Study 36207033 — intervention group
Group type: COMPARATOR
Intervention: Age, sex work duration, partner status, contraceptive use, and IPV experience
Number of subjects: 866
Study 33836822 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at menarche (AAM)
Number of subjects: 329345
Study 33836822 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at natural menopause (ANM)
Number of subjects: 329345
Study 33836822 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at first birth (AFB)
Number of subjects: 329345
Study 32775452 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Warning Labels (HWLs) on cigarette packs
Number of subjects: 240
Study 33619948 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit Training Group (CTG)
Number of subjects: 29
Study 33619948 — intervention group
Group type: EXPERIMENTAL
Intervention: Sets Training Group (STG)
Number of subjects: 29
Study 33619948 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 29
Study 32909229 — intervention group
Group type: EXPERIMENTAL
Intervention: Current appointment reminders
Number of subjects: 27
Study 32909229 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies used by patients to optimize reminders
Number of subjects: 27
Study 32909229 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for enhancing appointment reminders
Number of subjects: 27
Study 36116086 — intervention group
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy (WET)
Number of subjects: 46
Study 36116086 — intervention group
Group type: COMPARATOR
Intervention: Control (no additional contact)
Number of subjects: 46
Study 34371963 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed chicken collagen type II (HCII) supplement
Number of subjects: 90